Zur kombinierten kieferorthopädisch-kieferchirurgischen Behandlung von Säuglingen mit Lippen-Kiefer-Gaumenspalten

Zusammenfassung In der vorliegenden Arbeit werden Ziele und Aufgaben einerununterbrochenen kieferorthopädischen prä- und postoperativen Behandlung von Säuglingen mit Lippen-Kiefer-Gaumenspalten aufgezeigt. Die Methodik und der Behandlungsablauf werden beschrieben und die Ergebnisse an einzelnen Beispielen kritisch betrachtet.

---

Summary This paper is to present the purpose and function ofuninterrupted pre- and postoperative surgical and orthodontic treatment of babies with cleft lip and palate. The methods used and the progress of treatment are described. Finally, some results are reviewed critically.

---

Résumé Ce travail veut présenter les buts et tâches d'un traitement orthopédiqueininterrompu, avant et après la phase opératoire, chez des nourrissons atteints de division palatine et labiale. La méthode et les phases du traitement sont décrites ainsi que la critique de quelques résultats.

---

---

Mit 13 Abbildungen

---

Vortrag anläßlich der Wissenschaftlichen Jahrestagung der Deutschen Gesellschaft für Kieferorthopädie 1976 in Würzburg.

---

Ein Erstbericht aus chirurgischer Sicht wurde bereits in Hamburg 1975 anläßlich der Tagung der Deutschen Gesellschaft für Kiefer- und Gesichtschirurgie vonF. Schröder gegeben.

---

Die Patienten stammen aus der Klinik und Poliklinik für Kieferchirurgie (Direktor: Prof. Dr. Dr.F. Schröder) der Universität Würzburg. — Die Platten wurden im zahntechnischen Labor der Poliklinik für Kieferorthopädie (Direktor: Prof. Dr.E. Witt) hergestellt.     

Metabolism and excretion of 3H-digitoxin in the rat

After oral administration of 25 μg/kg ³H-labelled digitoxin (sp. act. 26.2 mCi/mg) to female rats, the total radioactivity in blood and in urine was eliminated with a half-life time of 2 and 1.7 days, respectively. The fecal elimination half-life time had a. biphasic course. The chloroform-soluble and chloroform-insoluble metabolites excreted in urine and feces were determined in order to explain the much shorter half-life time of 0.4 days in feces during the early phase of elimination. In the feces, 45 per cent of the dose excreted within 5 days consisted of chloroform-soluble substances. In this fraction, the main excretion product was digoxigenin-bis-digitoxoside (20 per cent), whereas the percentages of the other glycosides, after the last collection period, amounted to significantly less: 9% digitoxin, 9% digoxin. 5% digitoxigenin-bis-digitoxoside, and 2% digitoxigenin-mono-digitoxoside. The Chromatographic analysis of the chloroform-insoluble fraction, which accounted for 15 per cent of the dose. revealed a conjugation of glucuronic and sulfuric acid with digoxin, and digoxin, 5% digitoxigenin-bis-digitoxosidc. and 2% digitoxigenin-mono-digitoxoside. The contrast, sulfuric acid alone was the main conjugation partner of 3-epi-digitoxigenin. In urine, 4.6 per cent of the administered radioactivity was represented by digoxin, 2 per cent by digitoxin, 1 per cent by digoxigenin-bis-digitoxoside, and 1.4 per cent by polar metabolites. Only traces of digitoxigenin-bis-digitoxoside cind digoxigenin-mono-digitoxoside were detected. The much shorter half-life time of the eliminated radioactivity in feces seems to be due to the higher portion of poorly reabsorbed conjugation products and digoxigeninbis-digitoxoside.     

Gas chromatographic determination of urinary vanilglycolic acid, vanilglycol, vanilacetic acid and vanillactic acid-chemical parameters for the diagnosis of neurogenic tumours and the evaluation of their treatment.

A gas chromatographic method is described for the determination of urinary vanilglycolic acid, vanilglycol, vanilacetic acid and vanillactic acid as their trimethylsilyl derivatives. These metabolites are chemical parameters for the dignosis of neurogenic tumours. Their determination is especially recommended in order to evaluate the effect of the therapy. Results in normals and controls are given. Data in a number of selected patients with neuroblastoma, ganglioneuroma and phaeochromocytoma are presented and discussed.